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Abstract 
Releasing the patient’s immune system against their own malignancy by the use of checkpoint 
inhibitors is delivering promising results. However, only a subset of patients currently benefit from 
them. One major limitation of these therapies relates to the inability of T cells to detect or penetrate 
into the tumor resulting in unresponsiveness to checkpoint inhibition. Virotherapy is an attractive 
tool for enabling checkpoint inhibitors as viruses are naturally recognized by innate defense 
elements which draws the attention of the immune system. Besides their intrinsic immune 
stimulating properties, the adenoviruses used here are armed to express tumor necrosis factor alpha 
(TNFa) and interleukin-2 (IL-2). These cytokines result in immunological danger signaling and 
multiple appealing T-cell effects, including trafficking, activation and propagation. When these 
viruses were injected into B16.OVA melanoma tumors in animals concomitantly receiving 
programmed cell-death protein 1 (PD-1) blocking antibodies both tumor growth control (p<0.0001) 
and overall survival (p<0.01) were improved. In this set-up, the addition of adoptive cell therapy 
with OT-I lymphocytes did not increase efficacy further. When virus injections were initiated 
before antibody treatment in a prime-boost approach, 100% of tumors regressed completely and 
all mice survived. Viral expression of IL2 and TNFa altered the cytokine balance in the tumor 
microenvironment towards Th1 and increased the intratumoral proportion of CD8+ and 
conventional CD4+ T cells. These preclinical studies provide the rationale and schedule for a 
clinical trial where oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) is used in 
melanoma patients receiving an anti-PD-1 antibody.  
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Introduction 
The immunosuppressive microenvironment of solid tumors is one of the key features that protects 
them from effective antitumor immune responses1-3. In such an environment, both endogenously 
induced or adoptively transferred antitumor T cells switch into an exhausted state where their 
function is impaired4, 5. Checkpoint inhibitors are monoclonal antibodies designed to block specific 
suppressive pathways upregulated in many tumors 6. These antibodies have revolutionized the field 
of immunotherapy resulting in regulatory approval for the treatment of different types of cancers 
including melanoma, lung, renal, urothelial and other cancers, with more to follow. Despite 
impressive proof-of-concept long term efficacy in some patients, in fact only a relatively small 
subpopulation (10-50% of patients depending on tumor type) gain measurable benefit from 
checkpoint inhibition as a single-agent modality 6, 7. Amongst the major limitations of checkpoint 
blockade are situations where the tumor is invisible to the immune system (“cold” and “excluded” 
tumors)8, or situations where immune suppression is exerted through several pathways 
concurrently 9, 10. It is increasingly appreciated that checkpoint inhibition tends to work in “hot” 
tumors characterized by CD8+ lymphocyte infiltration, neoantigens and PD-L1 expression, while 
little efficacy is seen in “cold” or “immune excluded” tumors10.  
Given the increased understanding of the limitations of checkpoint blockade therapy, and the 
emerging mechanism-of-action data relating to oncolytic immunotherapy, the use of viral 
platforms is an appealing approach to overcome these obstacles. Due to mechanisms conserved 
during evolution, viruses are recognized by innate defense mechanisms resulting in two major 
consequences which are not subject to resistance mediated by tumor immunosuppression. 
Recognition of conserved viral patterns recruits immune cells to the tumor and converts the 
microenvironment towards a proimmunogenic one11, 12. Immunogenic viruses such as adenovirus, 
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are able to affect signaling in the tumor through several mechanisms, promoting the creation of 
new adaptive responses including those against tumor specific antigens13-15. Of note, anti-viral 
responses seem to contribute to anti-tumor responses through epitope spreading and danger 
signaling16. Translational benefits of these viral platforms for conversion of tumor-associated 
immunosuppression is embodied in the use of oncolytic viruses. They are an attractive tool for 
tumor immunotherapy as they are self-amplifying and their replication is restricted to the tumor, 
thus achieving high specificity for the target with limited adverse events17, 18. Systemic effects are 
achieved through the immune system and in the case of some viruses such as 5/3 chimeric 
adenovirus also through vascular dissemination19.   
There is currently a number of checkpoint inhibitors approved by regulatory agencies7 and the first 
oncolytic virus was approved by the FDA and EMA in 2015 for the treatment of unresectable 
melanoma20. There are, also, ongoing clinical trials where the effect after the combination of these 
two therapies is being studied21. Initial clinical data supports the notion that oncolytic virus can 
increase response rates without increasing toxicity22, in stark contrast to combinations of 
checkpoint inhibitors which increase both or in some cases just toxicities6. Since there is a plethora 
of checkpoints and their inhibitors, it was hypothesized that their combinations might improve 
efficacy. Given the frequency of patients that do not respond to checkpoint inhibition (50-80% 
depending on tumor type6), technologies are urgently needed to increase response rates.  
Previous data-driven work determined which clinically feasible cytokines provide the best synergy 
with tumor-recognizing T cells23. Tumor necrosis factor alpha (TNFa) and interleukin-2 (IL-2) 
were identified as the best arming devices in the context of tumor infiltrating lymphocyte (TIL) 
therapy and adoptive therapy with genetically modified anti-tumor T cells24, 25.  Since checkpoint 
blockade exerts its effects through T cells6, it became logical to study whether TNFa and IL-2 
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armed adenoviruses could be useful in this setting, with or without additional adoptive T cell 
transfer. 
 
Materials and methods 
Cell line and viruses. B16.OVA, a murine melanoma cell line, was kindly provided by Professor 
Richard Vile (Mayo Clinic, Rochester, MN, USA) and was cultured in RPMI 1640, supplemented 
with FBS (10%), L-Glutamine (2 mM), penicillin (100 U/mL), streptomycin (100 μg/mL) and G-
418 (5 mg/mL) under recommended conditions. The construction of Ad5-CMV-mIL2 and Ad5-
CMV-mTNFα adenoviruses is described elsewhere 24.   
In vivo studies. For each of the three animal experiments, 4-6 week old C57BL/6JOlaHsd mice 
were obtained (Envigo, Indianapolis, IN, USA) and housed in Biosafety level 2 facilities. After one 
week of quarantine the animals were subcutaneously engrafted with 2.5 x 105 B16.OVA cells in 
100 μl of plain RPMI 1640 in the left flank. When the tumors had a volume over 3 mm (around 
day 11) the animals were randomly divided into groups and treatments started. Tumors were 
measured at least every 3 days after starting the treatments during the first 15 days and then once 
per week with an electronic caliper. Tumor volume was calculated as 0.5 x longest diameter x 
(shortest diameter)2. Mice were observed daily and euthanized when tumor diameter exceeded 18 
mm, or at selected time-points for collection of biological samples. Animals for biological sample 
analysis were selected randomly and subsequently checked that they were representative of the 
whole group (no significant differences, after running t-test, between the original group and the 
selected for collection or the remaining animals). 
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Treatments. Viral treatments were given intratumorally with 30G insulin needles in 50 μL of 
phosphate buffered saline (PBS) with doses of 0.05-1 x 108 vp (with equal amounts of Ad5-CMV-
mIL2 and Ad5-CMV-mTNFα viruses) or PBS only in control groups. Anti-murine PD-1 (Clone 
RMPI-14, BioXCell) and the adoptive cell transfer therapy (CD8+ enriched population obtained 
from OT-I transgenic mice23) were injected intraperitoneally in 100 μL of RPMI 1640. The 
frequency of administration of the treatments in each experiment is provided in the respective 
figures. All injections were performed under isoflurane anesthesia. 
Flow cytometric analyses. After collection, tumors and spleens were passed through 70 μm cell 
strainers in order to get a single cell suspension and then centrifuged and resuspended in freezing 
media (90% FBS, 10% DMSO) for storage at -80ºC until flow cytometric analysis. Antibody 
staining for CD3 (PE-Cy5 conjugated, clone 145-2C11, Biolegend), CD8 (FITC conjugated, clone 
53-6.7, Biolegend), CD4 (FITC conjugated, clone GK1.5, Biolegend), PD-1 (PE-Cy7 conjugated, 
clone 29F.1A12), CTLA-4 (PE-dazzle conjugated, clone UC10-4B9, Biolegend), TIM-3 (PerCP-
Cy5.5 conjugated, clone RMT3-23, Biolegend), CD25 (PE-Cy7 conjugated, clone 3C7, Biolegend) 
and FoxP3 (PE conjugated, clone MF-14, Biolegend) were performed following manufacturer 
instructions. Recombinant MHC pentamers for the analysis of antigen-specific T cells (H-
2Kb/SIINFEKL, H-2Db/KVPRNQDWL, and H-2 Kb/SVYDFFVWL all of them PE conjugated 
from Proimmune) were used according to manufacturer instructions. At least 100,000 events were 
analyzed with the Sony SH800Z cytometer (Sony, Tokyo, Japan) under recommended use 
instructions. 
Cytometric Bead Array analysis.  Fragments of collected tumors were snap-frozen on dry ice 
and stored at -80ºC until analysis. Protein fraction of the samples was obtained as described 
previously23. Samples were stained with Cytometric Bead Array Mouse Th1/Th2/Th17 Cytokine 
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kit (560485, BD) and analyzed on BD Accuri C6 Cytometer (BD, Franklin Lakes, NJ, USA) with 
FCAP Array Software (BD, Franklin Lakes, NJ, USA) under manufacturer instructions. Cytokine 
expression was normalized to total protein present in the sample, using Warburg-Christian method 
after the values were obtained by spectrophotometry with Biophotometer (Eppendorf, Wesbury, 
NY, USA). 
Statistical analyses. SPSS (IBM, New York, NY, USA) version 24 was used to analyze the tumor 
volume evolution by linear mixed-model analysis of multiple time-correlated log-transformed 
normalized tumor volumes. GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA) was 
used to analyze overall survival (Kaplan-Meier survival estimates), and to evaluate differences in 
the biological samples by unpaired t test with Welch’s correction. Synergy assessed by Webb 
method as described before26. 
Ethical statement. All animal experiments in this study were performed in accordance with the 
recommendations in the Act on the Protection of Animals Used for Scientific or Educational 
Purpose (497/2013) and Government Decree on the Protection of Animals Used for Scientific or 
Educational Purposes (564/2013) as well as the European Directive 2010/63/EU. The protocols 
describing the work and procedures were approved by ethical committee from the National Animal 
Experiment Board of the Regional State Administrative Agency of Southern Finland.  
 
Results 
Virotherapy enables anti-PD-1 blockade and adoptive cell therapy: single-dose set-up  
The first study was designed as a proof of concept experiment in which both the viral treatment 
and the adoptive cell therapy (ACT) were given only once and the PD-1 blocking monoclonal 
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antibody was given 5 times (Figure 1A). In this set-up, all the therapies tested displayed superior 
(p<0.05) tumor growth control (Figure 1B), and improved overall survival (Figure 1C) over the 
saline treated control. Importantly, also checkpoint blockade alone exhibited a significant 
improvement in antitumor efficacy as compared with saline treated control, validating the selected 
administration frequency and dosing of the antibody. The best groups in this experiment were 
virotherapy combined with OT-I ACT or checkpoint blockade, or the three therapies together. 
When comparing double treatments, those including virus (i.e. Virus + anti-PD-1 or Virus + ACT) 
showed better tumor growth control (p<0.01) and overall survival (p<0.05) than the double group 
consisting of anti-PD-1 and ACT, indicating that virotherapy was the most relevant companion for 
both of the T-cell related therapy approaches tested.  
Checkpoint blockade delivers better tumor control than adoptive cell therapy when 
combined with virotherapy  
In order to identify the best candidate for the combination with the virotherapy, a second 
experiment was carried out with modifications in the virus dose and number of anti-PD-1 
treatments (Figure 2A). As the virus was identified as a key component in the proof of concept 
experiment, a reduced virus dose was used to highlight the role of OT-I cell transfer and anti-PD-
1 in the combination set-up, and select the one with stronger impact on the outcome of tumor 
control. Virus dose reduction resulted in non-significant (p=0.054) tumor growth control compared 
to virus monotherapy, but this group was studied later at full dose (see below). Also, the number 
of administrations of anti-PD-1 was increased to evaluate effects on long-term survival (Figures 
2B and 2C). When compared with the group treated with virus only, the only dual treatment that 
showed significant improvement on both tumor growth control (p<0.0001) and overall survival 
(p<0.001) was virus + anti-PD-1 therapy. When the three therapies were combined, better tumor 
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growth control (than virotherapy alone) is achieved (p<0.0001) but this did not result in a 
significant improvement in survival (p=0.072). The groups delivering the best results were virus + 
anti-PD-1 and the triple combination, with no significant differences between them.  
Tumors treated with anti-PD-1 and virotherapy display the most favorable TIL profile  
In the same experiment, 6 animals from each group were euthanized on day 12 to analyze their 
tumors, particularly the TIL subsets. The groups treated with virotherapy and anti-PD-1 displayed 
an increase in the frequency of intratumoral cytotoxic CD8+ T cells (Figure 3A). Considering the 
set-up of the study, special attention was paid on CD8+ TIL phenotype, especially in terms of 
expression of different checkpoint markers. Besides PD-1, for its particular involvement with one 
of the therapies, two other checkpoint pathways CTLA-4 and TIM-3 were studied. The percentage 
of PD-1+ CD8+ T cells was increased in the virotherapy + anti-PD-1 group (Figure 3B) and the 
expression of PD-1 in those cells was also upregulated (Figure 3C). The virus + anti-PD-1 group 
and more intensely the group receiving the three therapies, showed an increased amount of CD8+ 
cells positive for CTLA-4 (Figure 3D). A trend for increased numbers of TIM-3+ CD8 cells was 
observed only in the triple treated group (figure 3E). Regarding the levels of CTLA-4 and TIM-3 
in positive cells, there was no significant difference in expression patterns (mean fluorescence 
intensity, Supplementary figure 1).  
It is noteworthy that while PD-1 was abundantly expressed in all groups (average values between 
40-70%), the values were much lower for CTLA-4 (average values below 2%) and TIM-3 (average 
values below 1%). When studying the presence of tumor-specific T cells the two groups with best 
tumor control (virus + anti-PD-1 with or without ACT) showed an increase in OVA-specific TILs 
(Figure 3F). These tumor specific cells showed a similar pattern on PD-1, CTLA-4 and TIM-3 as 
the ungated CD8+ cell population (Supplementary figure 2). It should be noted that in the triple 
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and virus + ACT groups, some of the OVA specific T cells were probably cells of the OT-1 graft. 
Regarding the CD4+ compartment (Figure 3G), a significant increase in total CD3+ CD4+ cells 
was assessed only in the group treated with virus + anti-PD-1 while T-regulatory CD4+ cells (i.e. 
“Treg”) were increased only in the group treated with the virus as monotherapy (Figure 3H), while 
the conventional CD4+ T helper cell population, characterized  as CD3+ CD4+ CD25+ FoxP3- 
cells, was increased in all groups receiving viral therapy combined with either anti-PD-1 or ACT 
(Figure 3I).  
Optimized treatment regimen with virotherapy and PD-1 blockade results in complete 
responses  
In the third experiment (Figure 4A) virus and anti-PD-1 were administered at full dose. There were 
two groups treated with both the virus and the checkpoint inhibitor. In one of them, 15 rounds of 
both treatments were given simultaneously (through different administration routes). In the other 
group, the virus treatment was given 15 times while the anti-PD-1 treatment was started only with 
the third virus administration, resulting in a total of 13 cycles. Interestingly, optimizing the 
treatment protocol to mimic multiple rounds of both therapies as typical in patient treatment 
improved overall survival (Figure 4B) and led to better tumor growth control (Figure 4C) when 
anti-PD-1 and virotherapy were combined.  
Both double treatments were superior over any monotherapy and treatment synergy was observed 
(Supplementary figure 3). Moreover, in double-treated groups, tumors   were increasing in size for 
the first 10 days, up to 15-fold over the original volume, but after that, antitumor effects seemed to 
appear reducing large tumors to scars (probably lacking viable tumor cells), as seen in human 
immunotherapy trials27.  
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Tumor growth was controlled significantly better (p<0.01) with the prime and boost approach. This 
approach resulted in 100% of the animals remaining alive without tumors by day 90. Analysis of 
the survival curves indicated that prime and boost virotherapy with “delayed” anti-PD-1 resulted 
in the lowest hazard ratio when compared to anti-PD-1 alone (HR = 0.026 [0,005; 0,139]) or 
virotherapy alone (HR = 0.069 [0,015; 0,327])  
Cytokine-armed adenovirus drives the microenvironment of melanoma tumors towards a 
proinflammatory state  
The tumor microenvironment was studied by analyzing cytokine expression levels on day 11 (gray 
dotted line in Figure 4 indicates this time point). As expected, intratumoral expression of TNF and 
IL-2 (Figures 5A and 5B) were 10 times higher in groups that were treated with cytokine-
expressing viruses. This is most easily explained by the expression of these transgenes by the 
viruses. Interferon gamma on the other hand did not show any relevant changes across the groups 
(Figure 5C). The group delivering the best results in tumor control (virus + anti-PD-1 with the 
prime and boost strategy) also showed an increase in IL-4, IL-6 and IL-10 (Figures 5D-F). IL-17A 
expression (Figure 5G) was significantly upregulated in groups which received both anti-PD-1 and 
virotherapy. The expression of IL-17A is typically linked to “helper Th17” responses, so this data 
hints on the possible relevance of that T cell subset. When cytokines were grouped into 
proinflammatory Th1 (TNF, IL-2 and IFNg) or anti-inflammatory Th2 (IL4, IL6 ad IL10), 
cytokine-coding viruses were found to skew the cytokine balance of the tumors towards Th1 
(Figure 5H), suggesting that alteration of tumor microenvironment contributes to the anti-tumor 
effect seen. 
Long term survivors display increased presence of systemic tumor specific lymphocytes 
against different epitopes. 
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The presence and distribution of different tumor specific lymphocytes was studied from spleen 
samples collected on the experiment described in Figure 4A. First, 6-7 spleens per group were 
collected on day 11 and at day 90 all mice with complete responses were killed and their spleens 
were collected following identical procedures. Three different pentamers were used to study 
lymphocytes against three different tumor specific antigens: OVA, gp100 and Trp2. OVA is a 
model specific tumor epitope while the other two are “shared” melanoma epitopes. Those animals 
that responded to the treatments and had their tumors cleared displayed higher numbers (p<0.05) 
of tumor specific lymphocytes. When analyzing both time points separately, there were no 
remarkable differences between groups. Notably, on day 90, there was no significant variation 
between the groups treated with and without anti-PD-1. This suggests that anti-PD-1 might 
influence the activity but not frequency of the studied clones of tumor specific lymphocytes.  
Perhaps importantly, the proportion of tumor-recognizing T-cell clones was higher on day 90 than 
on day 11 in all groups. Probably all animals that made it to the end of the experiment had benefited 
from therapy. This proposes an association between anti-tumor T-cell immunity and survival in the 
context of melanoma bearing animals treated with viruses coding for TNFa and IL-2 and receiving 
anti-PD-1.  
 
Discussion 
The objective was to study the feasibility of using adenoviruses coding for TNFa and IL-2 to 
increase the efficacy of PD-1 checkpoint inhibition. Furthermore, the sequence of administration 
was optimized with relevance for clinical protocols. Previously, different viruses28-31 have been 
combined with checkpoint inhibitors but, to our knowledge, 100% long term survival has never 
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been previously achieved in this aggressive melanoma model32 used here. Previous results have, 
however, displayed benefits after the combination of viral platforms with checkpoint inhibitors 
such as anti-PD-129, 30 or PD-L128 among others. One reason for the promising efficacy seen in our 
approach over other reports could relate to the transgenes utilized. IL-2 and TNFa were selected in 
a rigorous data-driven process focusing on T-cell effects23. Previous results also pointed to an 
increased efficacy of ACT when they were coupled to this virus24  
We saw that virus treatment was able to polarize the tumor microenvironment towards an antitumor 
status as assessed by cytokine profile (Fig 5) but only when the virotherapy is combined with PD-
1 blockade the polarization is also seen at T-cell phenotype level (Fig 3). With regard to interaction 
between virotherapy and checkpoint blockade, the most likely explanation for synergy is that both 
treatments work towards the enhancement of anti-tumor specific cytotoxic cells, but without direct 
interaction between them; as two companions working in parallel towards the same purpose, but 
with different mechanism-of-action. Virotherapy has been proposed responsible for recruiting and 
activating cytotoxic T lymphocytes (CTLs) and modulating the immune microenvironment by 
expression of cytokines, and also through inherent alarm signals triggered after viral infection 
(pathogen associated molecular pattern receptors33). On the other hand, checkpoint blockade could 
be essential for preventing exhaustion of T cells recruited and stimulated by the virus. Also, 
blocking PD-1 may be important for prevention of immunosuppressive counter-responses which 
follow any prolonged immune response occurring in immune competent animals6. In normal 
situations the purpose of counter-response is to protect the body against autoimmunity, but this 
mechanism is hijacked by tumors for avoiding immune-mediated destruction6.  
The presence of TILs is considered one of the most important indicators of anti-tumor immunity34, 
35. Among TIL populations, those cells able to specifically recognize antigens (especially 
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neoantigens) expressed by the tumor cells are particularly relevant36. In the B16-OVA model used 
here, tumor cells are engineered to express a xenoantigen ovalbumin37, to enable studies of tumor 
specific T cells. Both subpopulations (CD3+ CD8+ and CD3+ CD8+ OVA+) were significantly 
increased in groups displaying the best anti-tumor results (Figs. 3A and 3F). This result is 
compatible with the notion that virus is able to recruit T cells to the tumor24. Besides the tumor 
specific TILs we also studied the presence of the relevant lymphocyte clones on the systemic level 
(Fig 6). In addition to OVA specific lymphocytes, we studied tumor specific lymphocytes against 
the Trp2 and gp100 antigens. While the ovalbumin is an antigen model-specific for B16.OVA cell 
line37, Trp2 and gp100 are widely expressed in a wide variety of melanomas38, 39. This allowed 
extension of our findings beyond the cell line used to other melanoma models.  
A different view on the presence of tumor specific responses can be obtained by comparing spleens 
on day 90 to spleens on day 11. The former were obtained from animals that benefited from therapy 
since they were alive. The latter represent initial stages of induction of the immune response. This 
comparison is particularly relevant when taken together with the data in Figure 3F. It seems that 
when tumors are present the groups treated with virus and anti-PD-1 show an increase in tumor 
specific lymphocytes at the tumor but not in the spleen. A hypothesis explaining this finding is that 
the treatments increase not only antitumor responses but also improve the trafficking to and 
proliferation at the tumor.   
Some of the cell types in the CD3+ CD4+ compartment also exert a beneficial role in tumor 
control35, while some other subsets like T-regulatory cells may act in an opposite manner40. Further 
subsets such as helper CD4+ cells contribute to antitumor responses41. In line with recent 
observations on the importance of CD4+ subpopulations, we found that the groups with best tumor 
control displayed high proportions of helper-like cells versus Tregs (Figs. 3G and 3H). Moreover, 
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IL-17 expression was upregulated in virus-treated tumors, suggesting an additional role for Th17-
like CD4+ cells. The fact that Th17 responses have been described to play a bipolar effect42, 43 on 
antitumor immunity might be influenced in this case by antiviral mechanisms enhancing the 
inflammatory Th17 effects as studied in other immune-related diseases44, 45. 
Another relevant issue is the selection of the checkpoint inhibitor. There is a relatively wide variety 
of options (at least preclinically) and there is currently a lack of deep understanding on their 
respective optimal use. Based on the expression profiles of inhibitory pathways in the melanoma 
model used here, the most widely expressed inhibitory signal seems to come from the PD-1 
pathway rather than CTLA-4 or TIM-3 (Fig 3), albeit every pathway has different mechanisms of 
action making head-to-head comparisons of absolute inhibitory effect on lymphocytes difficult6, 46. 
Therefore, it could be theorized that in this particular model the use of therapeutic anti-PD-1 
antibodies might provide higher benefit than others (e.g. anti-CTLA-4, anti-TIM-3). Others studied 
different combinations of checkpoint inhibitors with virotherapy with somewhat similar28, 30, 31, 47 
or opposite outcomes29, which depicts the need for further understanding of these inhibitory 
pathways.  
Depending on the particular expression levels of the different inhibitory routes, the achievement of 
a clear antitumor immune response might be heavily dependent on the blockade of a specific route. 
For example, in one of the conditions tested in this study (Fig 2) the group treated with virotherapy, 
checkpoint inhibitors and ACT did not perform better than groups with fewer therapies, 
hypothetically due to high levels of non-blocked PD-1 receptors on the surface of the TILs (Fig 3). 
Similarly, the group treated with the three therapies (i.e. virotherapy, anti-PD-1 and ACT) might 
have upregulated secondary inhibitory routes such as CTLA-4 (Supplementary figure 2B) as a 
counter response of the stronger initial response. 
16 
 
To add more uncertainty to the understanding of the presence of checkpoint markers, some of them 
as PD-1 and CTLA-4 are expressed on the surface of cytotoxic lymphocytes after their activation6. 
This phenomenon, might lead to ambiguous interpretation of the data as the mere presence of the 
proteins is not automatically a detrimental feature when analyzing biological samples and actually 
might mean a higher antitumor efficacy 48, 49 if the potential inhibitory effect coming after they 
bind their ligands is avoided (e.g. by the use of an inhibitory antibody).  
When studying the tumor microenvironment, it has been claimed that intratumoral injection of 
cytokines can result in tumor control or beneficial effects on the tumor microenvironment23, 50, 51 
with no need of specific cell populations able to produce those cytokines. In this regard, viruses 
are a convenient tool to deliver cytokines locally, resulting in extended high level expression 
without significant systemic exposure51, 52. Also, the innate proinflammatory effects of the virus 
are amplified in the tumor microenvironment by viral transgene expression (TNFa and IL-2). This 
is a likely reason why there is an increase (Fig 5H) in Th1 cytokines which may contribute to a 
favorable inflammatory status with subsequent antitumor effects53, 54. Due to the immune 
homeostasis55, a Th2 response typically follows any Th1 response. However, when the 
upregulation of Th1 and Th2 cytokines in the tumor are compared, the former were expressed 16.8-
fold higher on average while the latter were increased only 3.4-fold in virus treated groups. 
Regarding Th17 signals, their role is more controversial as they could lead to both antitumor (e.g. 
CD8+ cell activation, intratumoral immune cell recruitment) and protumor (e.g. angiogenesis, 
myeloid-derived suppressor cells recruitment) changes43, 56, 57.  
The field of immunotherapy has evolved steadily in the last decade but the excitement caused by 
long-term responses in some patients is frequently coupled with frustrating ignorance regarding 
optimal combinations, dosing and administration regimes. In this regard, we addressed the 
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sequencing of virotherapy with checkpoint blockade. A better outcome was seen when checkpoint 
blockade was started after a priming period of virotherapy given as monotherapy. We hypothesized 
that the initial virus injections alone (i.e. without concomitant anti-PD-1 administration) might 
allow the virus to “exploit” tumor immunosuppression for avoiding anti-viral immunity while 
generating anti-tumor immunity. Further studies are needed in this regard 
 Our results provide the rationale to study the same question with other viruses - it is possible that 
priming before initiation of anti-PD1 is useful for many types of viruses. It is pertinent to note that 
the phase Ib trial of T-VEC in combination with pembrolizumab featured a priming period with 
virus injections before anti-PD-1 was started22. In contrast, the phase III trial which followed 
featured simultaneous administration of both drugs without priming. If there is an efficacy 
difference between these trials, this difference in administration could be an important reason. Our 
data suggests that it is not trivial how and when the drugs are given.  
In summary, we report 100% cure rates and 100% survival when mice with aggressive 
immunosuppressive melanoma (similar to many human melanoma patients) were injected with 
adenoviruses coding for TNFa and IL-2, with subsequent initiation of anti-PD-1 therapy in a prime 
and boost manner. Mechanistic clues suggest that this regime induced proinflammatory danger 
signals in the tumor microenvironment and led to effective recruitment and stimulation of anti-
tumor T cells, whose exhaustion was prevented by the anti-PD-1 antibody. These results set the 
stage for clinical evaluation of an oncolytic adenovirus coding for TNFa and IL-2 (TILT-123)25 in 
melanoma patients receiving anti-PD-1 antibody. 
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Figure 1. Proof of concept antitumor efficacy and overall survival after the combination of virotherapy 
with checkpoint blockade and adoptive cell therapy. A) 7-8 animals per group received subcutaneous 
B16.OVA tumors that were grown for 11 days. Then, 1 x 108 viral particles of non-replicating adenoviruses 
22 
 
(coding for mIL2 and mTNFa) or PBS were injected intratumorally. The same day, depending on the group 
they belonged, 2 x 106 CD8+ OT-1 T cells were adoptively transferred and/or 0.1 mg of anti-PD-1 were 
injected. Anti-PD-1 treatment was repeated 5 more times every 3 days. B) Normalized mean tumor volume 
and SEM at day 15. C) Overall survival.  
 
 
Figure 2. Antitumor efficacy and overall survival after the combination of low dose virotherapy with 
checkpoint blockade and adoptive cell therapy. A) Subcutaneous B16.OVA tumors were grown for 10 
days. Then mice received i.t. 5 x 106 viral particles of non-replicating adenoviruses coding for mIL2 and 
mTNFa or PBS. The same day, depending on the group they belonged, 2 x 106 CD8+ OT-1 T cells were 
adoptively transferred and/or 0.1 mg of anti-PD-1. Checkpoint blockade treatment was repeated 9 more 
times every 3 days. 6 random animals from each group were euthanized at day 12 and organs were 
collected for further analysis, the remaining animals (9-12) were maintained for survival studies. B) Overall 
survival and statistical significances. C) Individual tumor growth lines for the different conditions tested 
and statistical significance of the differences between groups at day 12.   
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Figure 3. Phenotypical analysis of tumor infiltrating lymphocytes 13 days after the different treatments 
started. A) Percentage CD3+ CD8+ cells of total cells in the tumor. B) Percentage of PD-1+ lymphocytes of 
parent population (CD3+ CD8+). C) Mean fluorescence intensity of the channel used for anti-PD-1. D) 
Percentage of CTLA-4+ lymphocytes of parent population (CD3+ CD8+). E) Percentage of TIM-3+ 
lymphocytes of parent population (CD3+ CD8+). F) Percentage of OVA-specific lymphocytes of parent 
population (CD3+ CD8+). G) Percentage CD3+ CD4+ cells of total cells in the tumor. H) Percentage of 
Regulatory T cells (CD25+ FoxP3+) of parent population (CD3+ CD4+). I) Percentage of conventional CD4 T 
cells (CD25+ FoxP3-) of parent population (CD3+ CD4+). 
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Figure 4. Antitumor efficacy and overall survival in a clinically relevant set up after the combination of 
virotherapy with checkpoint blockade. A) 12-16 animals per group received subcutaneous B16.OVA 
tumors that were grown for 10 days. Then mice received i.t. 1 x 108 viral particles of non-replicating 
adenoviruses coding for mIL2 and mTNFa or PBS. The same day, depending on the group they belonged, 
they received 0.1 mg of anti-PD-1. Checkpoint blockade treatment was repeated every 3 days for a total 
of 13-15 times. At day 4, 7 untreated animals engrafted with the same tumors were sacrificed to study the 
status of the tumor at “baseline” time point. 6-7 random animals from each group were euthanized at day 
11 (grey line) and organs were collected for further analysis, remaining animals were maintained for 
survival studies. B) Overall survival and statistical significances. C) Individual tumor growth lines for the 
different conditions tested and statistical significance of the differences between groups at day 39.  
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Figure 5. Cytokine profile expression of tumor samples 11 days after the different treatments started. 
All values are normalized by the cytokine expression of the mock mean value A) Tumor necrosis factor. B) 
Interleukin-2. C) Interferon gamma. D) Interleukin-4. E) Interleukin-6. F) Interleukin-10. G) Interleukin-17A 
(also studied as Th17 signal representative cytokine). H) Comparison of pooled Th1 (TNF, IL-2 and IFNg) 
and Th2 (IL-4, IL-6 and IL-10) cytokines present in the tumor microenvironment. 
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Figure 6. Presence of tumor specific CD8 cells in spleens at two different time points. Stacked 
percentages of OVA/gp100/Trp2 specific CD8+ CD3+ splenocytes. Samples from day 11 (n=6-7) and from 
survivors at day 90 (n=2 from virus alone group, n=6 from virus + anti-PD-1[simultaneous] and n=9 from 
virus + anti-PD-1 [prime and boost]). 
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Supplementary Figure 1. Abundance of certain checkpoint receptors in tumor infiltrating lymphocytes. 
A) Mean fluorescence intensity of the channel for anti-CTLA-4 of CD3+ CD8+ population. B) Mean 
fluorescence intensity of the channel for anti-TIM-3 of CD3+ CD8+ population. 
 
 
Supplementary Figure 2. Expression of different checkpoint molecules on the surface of tumor specific 
lymphocytes. A) Percentage of PD-1+ lymphocytes of parent population (CD3+ CD8+ OVApentamer+). B) 
Percentage of CTLA-4+ lymphocytes of parent population (CD3+ CD8+ OVApentamer+). C) Percentage of 
TIM-3+ lymphocytes of parent population (CD3+ CD8+ OVApentamer+) D) Mean fluorescence intensity of 
the channel for anti-PD-1 of CD3+ CD8+ OVApentamer+ population. E) Mean fluorescence intensity of the 
channel for anti-CTLA-4 of CD3+ CD8+ OVApentamer+ population. F) Mean fluorescence intensity of the 
channel for anti-TIM-3 of CD3+ CD8+ OVApentamer+ population. 
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Supplementary Figure 3. Evaluation of the synergistic effect between virotherapy and checkpoint 
blockade. Normalized mean volumes from day 12 used for the calculi. A) Fractional tumor volume (FTV) 
formula. B) Synergy formula, synergistic effect is assessed when Synergy index is >1. C) FTV and Synergy 
index calculated for different groups. 
 
